Home > Insider Trading > Filing (0001140361-17-002340)

Filing Details

Accession Number:: 0001140361-17-002340
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-01-19 21:15:49
Reporting Period:: 2017-01-17

Filing Date:: 2017-01-19
Accepted Time:: 2017-01-19 21:15:49
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1367644	Emergent Biosolutions Inc.	EBS	Pharmaceutical Preparations (2834)	141902018

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1514588	Adam Havey	400 Professional Dr, Suite 400 Gaithersburg MD 20879	Evp, Biodefense Divison	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-08-01	452	$0.00	41,424	No	4	J	Direct
Common Stock	Acquisiton	2016-08-01	599	$0.00	42,023	No	4	J	Direct
Common Stock	Acquisiton	2016-08-01	748	$0.00	42,771	No	4	J	Direct
Common Stock	Disposition	2017-01-17	8,438	$29.75	34,333	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	J	Direct
No	4	J	Direct
No	4	J	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to buy)	Acquisiton	2016-08-01	577	$0.00	577	$22.03
Common Stock	Stock Option (Right to buy)	Acquisiton	2016-08-01	1,386	$0.00	1,386	$22.03
Common Stock	Stock Option (Right to buy)	Acquisiton	2016-08-01	2,709	$0.00	2,709	$25.62
Common Stock	Stock Option (Right to buy)	Acquisiton	2016-08-01	1,794	$0.00	1,794	$26.45
Common Stock	Stock Option (Right to buy)	Acquisiton	2016-08-01	1,495	$0.00	1,495	$30.86

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
6,573	2018-03-14	No	4	J	Direct
15,770	2018-03-14	No	4	J	Direct
30,828	2021-03-10	No	4	J	Direct
20,414	2022-03-09	No	4	J	Direct
17,009	2023-02-28	No	4	J	Direct

Footnotes

In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units asa result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017.
In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units asa result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017 and March 2018.
In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units asa result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017, March 2018 and March 2019.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.48 to $30.15, inclusive.
Consists of an option granted on 03/15/2011 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.
The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.
Consists of an option granted on 03/11/2014 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.
Consists of an option granted on 03/10/2015 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.
Consists of an option granted on 03/01/2016 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.